Introduction
Quinolones became available for treatment of gonorrhoea in the mid-1980s and since 1989 they have been used as a single-dose oral therapy. Quinolone resistance in Neisseria gonorrhoeae has been reported mostly in the Far East, the Philippines, Hong Kong and Japan. Less quinolone resistance has been reported in Australia, the USA and Europe.
Mutations in the gyrA and parC genes, which lead to alterations in the GyrA and ParC subunits of DNA gyrase and topoisomerase, respectively, have a central role in resistance to fluoroquinolones. 1, 2 Resistance to various antibacterial agents: penicillins, tetracyclines, macrolides, fluoroquinolones and hydrophobic antibacterial agents produced by the host itself (fatty acids, antibacterial peptides) can also be predetermined by mutations in the promoter or encoding region of the mtrR gene, which leads to increased action by the MtrCMtrD-MtrE efflux system. 3, 4 Strains of N. gonorrhoeae resistant to ciprofloxacin 5 and norfloxacin 6 were shown to have decreased bacterial cell permeability to fluoroquinolones. This is possibly connected with a series of amino acid changes in the Por protein, as is the case with resistance to penicillin and tetracycline. 7 According to previous studies of N. gonorrhoeae in Russia, only sporadic isolates with low-level ciprofloxacin resistance (MICs 0.125-0.5 mg/L) were found in 1998. 8 However, larger numbers of isolates with high-level fluoroquinolone resistance were found in the sexually transmitted diseases clinic in the Moscow region during a surveillance programme established in Russia in 2002.
The aim of the present work was to determine the molecular mechanisms of resistance and to assess the clonal relationship of strains.
Materials and methods

Bacterial strains
Thirty-two clinical strains of N. gonorrhoeae isolated from patients with uncomplicated gonorrhoea in Moscow and the Moscow region in 2002 were studied.
Antimicrobial susceptibility testing
MICs of ciprofloxacin and moxifloxacin (both from Bayer AG, Germany), and levofloxacin and ofloxacin (both from Aventis Pharma S.A., France) were determined by an agar dilution technique 9 using GC agar (bioMérieux, France) supplemented with PolyViteX (bioMérieux, France). N. gonorrhoeae ATCC 49226 was used as a control. All tests were performed in triplicate. The antimicrobial susceptibility was judged according to breakpoint criteria defined by the NCCLS. 9 The respective concentrations for susceptible/intermediate/resistant breakpoints were ≤0.06/0.125-0.5/≥1 mg/L for ciprofloxacin and ≤0.25/0.5-1/≥2 mg/L for ofloxacin. NCCLS breakpoints for moxifloxacin and levofloxacin have not been determined.
DNA isolation and amplification of N. gonorrhoeae genome fragments
Total DNA of N. gonorrhoeae was isolated according to the method of Boom et al. 10 Previously recommended primers 1,2,4,11 were used to amplify the quinolone resistance determining regions of the gyrA and parC genes, the promoter and a fragment of the encoding region of the mtrR gene and the por gene. The PCR amplification was carried out in a reaction mixture containing 10 mM Tris-HCl pH 9.0, 50 mM KCl, 2 mM MgCl 2 , 250 µM each dNTP, 1 unit Taq polymerase (Promega, USA) and 10 pmol of each primer, using the thermocycler 'Tercyc' (DNA-Technology, Russia). The products of amplification were analysed in a 2% agarose gel.
Determination of the nucleotide and amino acid sequences
The amplification products were purified on the Wizard PCR Preps DNA Purification System (Promega, USA), for determination of the nucleotide sequences. Sequencing of the gene (por, gyrA, parC, mtrR) fragments was carried out using the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit and the ABI Prism 3100 Genetic Analyser (Applied Biosystems, USA; Hitachi, Japan). The full-scale sequence of the por gene was obtained by means of assembling the nucleotide fragments using the software product 'Vector NTI Suite v. 6.0' (InforMax, Inc., USA).
The amino acid sequences of GyrA, ParC and MtrR were determined from the known nucleotide sequences using the software 'Vector NTI Suite v. 6.0' (InforMax, Inc.).
Por typing of N. gonorrhoeae strains
The Por type of the strains was determined by identifying the obtained nucleotide sequences of the por genes in the EMBL (European Molecular Biology Laboratory) and NCBI (National Centre for Biotechnology Information) databases. Table 1 shows susceptibility data for 32 N. gonorrhoeae strains with details of Por type, GyrA, ParC, MtrR and Por alterations and mtrR gene promoter mutations.
Results and discussion
The 32 strains studied can be divided into two groups. Strains in the first group (n = 10) were fully susceptible to fluoroquinolones Previously, Shultz et al. 12 showed that strains having mutations simultaneously in GyrA and ParC exhibited a higher level of resistance than strains having mutations only in GyrA, with the maximal MIC values being shown for the strains having mutations in both GyrA and ParC. According to our study, no such pattern could be discerned (Table 1) .
Amino acid substitutions known to lead to development of fluoroquinolone resistance were identified in 17 of 21 phenotypically resistant strains. Among the strains examined, we revealed no single mutations in GyrA and this agrees with the absence of strains with lowlevel fluoroquinolone resistance; only double GyrA mutations were detected. Double GyrA mutations (Ser-91→Phe, Asp-95→Gly) were combined with the ParC mutation Ser-87→Arg in seven isolates. In addition, double GyrA mutations (Ser-91→Phe, Asp-95→Asn) were combined with the ParC mutation Glu-91→Gly in two strains. In one strain without any GyrA mutations, the ParC mutation Glu-91→Gly was detected. In our opinion, this is the first finding of a clinical isolate with high-level fluoroquinolone resistance due to a single firststep mutation in parC. It was possible to determine five genotypes in the examined isolates, indicating their genetic heterogeneity. Apparently, in the Moscow region, independent processes of selection and accumulation of fluoroquinolone-resistant strains take place.
In cases of fluoroquinolone resistance without mutations in the GyrA and ParC proteins (four strains) one could surmise the existence of unknown alterations in gyrase and topoisomerase genes.
It is proposed that mutations in the promoter and the encoding region of the mtrR gene may contribute to fluoroquinolone resistance in N. gonorrhoeae due to increased expression of the proteins of the MtrCDE system. 3 Analysis of the polymorphism of the mtrR gene and its promoter in the examined samples showed that 21 strains had mutations in the promoter and/or substitution at amino acid position 45 of the MtrR protein. The majority of them (20 strains) had only one of the two possible mutations. We showed that eight of 10 fluoroquinolone-susceptible strains also had this mutation (Table 1) .
Analysis of the polymorphism of Por at positions 120 and 121 showed that 22 strains had amino acid substitutions in the Por protein that decrease bacterial cell permeability for penicillin and tetracycline. 7 No correlation between amino acid substitutions and the level of fluoroquinolone resistance was found.
Thus our data did not confirm the possible role of reduced cell permeability and efflux in N. gonorrhoeae resistance to fluoroquinolones.
Por typing revealed genetic heterogeneity among the isolates studied. Thirty-one strains belonged to the PIB serovar (PIB3, 41.9%; PIB2, 19.4%; PIB5, 12.9%; PIB7, 9.7%; PIB3/5, 6.5%; PIB4, 3.2%; PIB3/6, 3.2%; PIB8, 3.2%) and one strain belonged to the PIA serovar.
This work documents the first detection of quinolone-resistant N. gonorrhoeae in Russia. The results of the genetic analysis lead us to conclude that this fact is not a local phenomenon predetermined by distribution of one or a limited number of clones. Hence, in spite of the limited number of samples, these results are important for planning antibacterial therapy of gonorrhoea in the Moscow region. It should be noted that the number of studied isolates is insufficient to extrapolate results to the whole of Russia. Regional surveillance studies on the prevalence of fluoroquinolone resistance in N. gonorrhoeae are essential.
